Copyright © 2008 Elias J. Gialafos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. P. Denton, C. M. Black, and D. J. Abraham, “Mechanisms and consequences of fibrosis in systemic sclerosis,” Nature Clinical Practice Rheumatology, vol. 2, no. 3, pp. 134–144, 2006. View at Publisher · View at Google Scholar · View at PubMed
2. C. Charles, P. Clements, and D. E. Furst, “Systemic sclerosis: hypothesis-driven treatment strategies,” The Lancet, vol. 367, no. 9523, pp. 1683–1691, 2006. View at Publisher · View at Google Scholar · View at PubMed
3. T. M. Bull, “Screening and therapy of pulmonary hypertension in systemic sclerosis,” Current Opinion in Rheumatology, vol. 19, no. 6, pp. 598–603, 2007. View at Publisher · View at Google Scholar · View at PubMed
4. H. Nagase and K. Brew, “Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors,” Biochemical Society Symposium, no. 70, pp. 201–212, 2003.
5. I. Koskivirta, O. Rahkonen, M. Mäyränpää, et al., “Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology,” Histochemistry and Cell Biology, vol. 126, no. 3, pp. 335–342, 2006. View at Publisher · View at Google Scholar · View at PubMed
6. K. Kuroda and H. Shinkai, “Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis,” Archives of Dermatological Research, vol. 289, no. 10, pp. 567–572, 1997. View at Publisher · View at Google Scholar
7. L. Mattila, K. Airola, M. Ahonen, et al., “Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts,” Journal of Investigative Dermatology, vol. 110, no. 4, pp. 416–421, 1998. View at Publisher · View at Google Scholar · View at PubMed
8. J. Greene, M. Wang, Y. E. Liu, L. A. Raymond, C. Rosen, and Y. E. Shi, “Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4,” The Journal of Biological Chemistry, vol. 271, no. 48, pp. 30375–30380, 1996. View at Publisher · View at Google Scholar
9. J. Fielitz, M. Leuschner, H. R. Zurbrügg, et al., “Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis,” Journal of Molecular Medicine, vol. 82, no. 12, pp. 809–820, 2004. View at Publisher · View at Google Scholar · View at PubMed
10. L. E. Felkin, E. J. Birks, R. George, et al., “A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support,” The Journal of Heart and Lung Transplantation, vol. 25, no. 12, pp. 1413–1419, 2006. View at Publisher · View at Google Scholar · View at PubMed
11. B. Stratmann, M. Farr, and H. Tschesche, “MMP-TIMP interaction depends on residue 2 in TIMP-4,” FEBS Letters, vol. 507, no. 3, pp. 285–287, 2001. View at Publisher · View at Google Scholar
12. M. H. Williams, C. E. Handler, R. Akram, et al., “Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension,” European Heart Journal, vol. 27, no. 12, pp. 1485–1494, 2006. View at Publisher · View at Google Scholar · View at PubMed
13. P. P. Sfikakis, M. Kyriakidis, C. Vergos, et al., “Diffusing capacity of the lung and nifedipine in systemic sclerosis,” Arthritis & Rheumatism, vol. 33, no. 11, pp. 1634–1639, 1990. View at Publisher · View at Google Scholar
14. Ch. Kostopoulos, J. Koutsikos, C. Toubanakis, et al., “Lung scintigraphy with nonspecific human immunoglobulin G ( ${}^{99\text{m}}\text{T}\text{C}$-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 343–351, 2008. View at Publisher · View at Google Scholar · View at PubMed
15. I. Moyssakis, E. Gialafos, V. Vassiliou, et al., “Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement,” Rheumatology, vol. 44, no. 2, pp. 251–254, 2005. View at Publisher · View at Google Scholar · View at PubMed
16. C. Tei, K. S. Dujardin, D. O. Hodge, et al., “Doppler echocardiographic index for assessment of global right ventricular function,” Journal of the American Society of Echocardiography, vol. 9, no. 6, pp. 838–847, 1996. View at Publisher · View at Google Scholar
17. B. M. McQuillan, M. H. Picard, M. Leavitt, and A. E. Weyman, “Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects,” Circulation, vol. 104, no. 23, pp. 2797–2802, 2001. View at Publisher · View at Google Scholar
18. D. Mukerjee, D. St. George, C. Knight, et al., “Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis,” Rheumatology, vol. 43, no. 4, pp. 461–466, 2004. View at Publisher · View at Google Scholar · View at PubMed
19. E. C. LeRoy, C. Black, R. Fleischmajer, et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988.
20. A. J. MacGregor, R. Canavan, C. Knight, et al., “Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival,” Rheumatology, vol. 40, no. 4, pp. 453–459, 2001. View at Publisher · View at Google Scholar
21. G. Giannelli, F. Iannone, F. Marinosci, G. Lapadula, and S. Antonaci, “The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension,” Current Medical Research and Opinion, vol. 21, no. 3, pp. 327–332, 2005. View at Publisher · View at Google Scholar · View at PubMed
22. S. Trad, Z. Amoura, C. Beigelman, et al., “Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease,” Arthritis & Rheumatism, vol. 54, no. 1, pp. 184–191, 2006. View at Publisher · View at Google Scholar · View at PubMed
23. H. Li, H. Simon, T. M. A. Bocan, and J. T. Peterson, “MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition,” Cardiovascular Research, vol. 46, no. 2, pp. 298–306, 2000. View at Publisher · View at Google Scholar
24. U. Seeland, I. Kouchi, O. Zolk, G. Itter, W. Linz, and M. Böhm, “Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts,” Journal of Molecular and Cellular Cardiology, vol. 34, no. 2, pp. 151–163, 2002. View at Publisher · View at Google Scholar · View at PubMed
25. D. D. Bonnema, C. S. Webb, W. R. Pennington, et al., “Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs),” Journal of Cardiac Failure, vol. 13, no. 7, pp. 530–540, 2007. View at Publisher · View at Google Scholar · View at PubMed
26. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett, Jr., “Plasma brain natriuretic peptide concentration: impact of age and gender,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 976–982, 2002. View at Publisher · View at Google Scholar
27. K. T. Spencer, J. N. Kirkpatrick, V. Mor-Avi, J. M. Decara, and R. M. Lang, “Age dependency of the Tei index of myocardial performance,” Journal of the American Society of Echocardiography, vol. 17, no. 4, pp. 350–352, 2004. View at Publisher · View at Google Scholar · View at PubMed
28. Y. Allanore, D. Borderie, J. Avouac, et al., “High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 284–291, 2008. View at Publisher · View at Google Scholar · View at PubMed
29. E. Toubi, A. Kessel, G. Grushko, E. Sabo, M. Rozenbaum, and I. Rosner, “The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221–224, 2002.
30. N. Yazawa, K. Kikuchi, H. Ihn, et al., “Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 42, no. 1, part 1, pp. 70–75, 2000. View at Publisher · View at Google Scholar
31. G. Giannelli, F. Iannone, F. Marinosci, G. Lapadula, and S. Antonaci, “Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs,” European Journal of Clinical Investigation, vol. 36, pp. 73–77, 2006. View at Publisher · View at Google Scholar · View at PubMed
32. B. Dziankowska-Bartkowiak, E. Waszczykowska, A. Zalewska, and A. Sysa-Jędrzejowska, “Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients,” Mediators of Inflammation, vol. 2005, no. 3, pp. 144–149, 2005. View at Publisher · View at Google Scholar · View at PubMed
33. A. Shahin, A. Elsawaf, S. Ramadan, O. Shaker, M. Amin, and M. Taha, “Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities,” Mediators of Inflammation, vol. 2006, Article ID 38458, 6 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
34. S. A. Young-Min, C. Beeton, R. Laughton, et al., “Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls,” Annals of the Rheumatic Diseases, vol. 60, no. 9, pp. 846–851, 2001.
35. W.-U. Kim, S.-Y. Min, M.-L. Cho, et al., “Elevated matrix metalloproteinase-9 in patients with systemic sclerosis,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R71–R79, 2005. View at Publisher · View at Google Scholar · View at PubMed
36. P. P. Sfikakis, B. K. McCune, M. Tsokos, K. Aroni, G. Vayiopoulos, and G. C. Tsokos, “Immunohistological demonstration of transforming growth factor-$\beta$ isoforms in the skin of patients with systemic sclerosis,” Clinical Immunology and Immunopathology, vol. 69, no. 2, pp. 199–204, 1993. View at Publisher · View at Google Scholar
37. F. Verrecchia, J. Laboureau, O. Verola, et al., “Skin involvement in scleroderma: where histological and clinical scores meet,” Rheumatology, vol. 46, no. 5, pp. 833–841, 2007. View at Publisher · View at Google Scholar · View at PubMed
38. Y.-P. Han, T.-L. Tuan, M. Hughes, H. Wu, and W. L. Garner, “Transforming growth factor-$\beta$- and tumor necrosis factor-$\alpha$ -mediated induction and proteolytic activation of MMP-9 in human skin,” The Journal of Biological Chemistry, vol. 276, no. 25, pp. 22341–22350, 2001. View at Publisher · View at Google Scholar · View at PubMed
39. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, et al., “Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension,” Circulation Research, vol. 94, no. 8, pp. 1101–1108, 2004. View at Publisher · View at Google Scholar · View at PubMed
40. G. Bou-Gharios, J. Osman, C. Black, and I. Olsen, “Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis,” Clinica Chimica Acta, vol. 231, no. 1, pp. 69–78, 1994. View at Publisher · View at Google Scholar
41. A. Vieillard-Baron, E. Frisdal, S. Eddahibi, et al., “Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats,” Circulation Research, vol. 87, no. 5, pp. 418–425, 2000.
42. W. Briest, L. Homagk, H. A. Baba, et al., “Cardiac remodeling in erythropoietin-transgenic mice,” Cellular Physiology and Biochemistry, vol. 14, no. 4–6, pp. 277–284, 2004. View at Publisher · View at Google Scholar · View at PubMed
43. C. M. Tummalapalli, B. J. Heath, and S. C. Tyagi, “Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts,” Journal of Cellular Biochemistry, vol. 80, no. 4, pp. 512–521, 2001. View at Publisher · View at Google Scholar
44. C. A. Fernández and M. A. Moses, “Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4,” Biochemical and Biophysical Research Communications, vol. 345, no. 1, pp. 523–529, 2006. View at Publisher · View at Google Scholar · View at PubMed
45. U. Seeland, C. Haeuseler, R. Hinrichs, et al., “Myocardial fibrosis in transforming growth factor-$\beta$1 (TGF-$\beta$1) transgenic mice is associated with inhibition of interstitial collagenase,” European Journal of Clinical Investigation, vol. 32, no. 5, pp. 295–303, 2002. View at Publisher · View at Google Scholar
46. I. T. W. Harley, K. M. Kaufman, J. M. Guthridge, et al., “Whole genome association by DNA pooling leads to interesting candidate genes for systemic sclerosis,” Arthritis & Rheumatism, vol. 56, p. S65, 2007.
47. P. P. Sfikakis and G. C. Tsokos, “Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations,” Clinical and Experimental Rheumatology, vol. 13, no. 6, pp. 763–777, 1995.